(IN BRIEF) QIAGEN has announced FDA clearance for its QIAstat-Dx Respiratory Panel Mini, marking the third such approval for the QIAstat-Dx system in 2024. Tailored for outpatient settings, this panel quickly detects five common respiratory pathogens—including influenza strains and SARS-CoV-2—enabling … Read the full press release →
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged FDA approval, influenza strains, Nadia Aelbrecht, Outpatient Respiratory Diagnostics, QIAGEN, QIAstat-Dx Mini Panel, Rapid Results, safety, SARS-CoV-2